|
1
|
Augustine MM and Fong Y: Epidemiology and
risk factors of biliary tract and primary liver tumors. Surg Oncol
Clin North Am. 23:171–188. 2014. View Article : Google Scholar
|
|
2
|
Shaib Y and El-Serag HB: The epidemiology
of cholangiocarcinoma. Semin Liver Dis. 24:115–125. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
van der Gaag NA, Kloek JJ, de Bakker JK,
Musters B, Geskus RB, Busch OR, Bosma A, Gouma DJ and van Gulik TM:
Survival analysis and prognostic nomogram for patients undergoing
resection of extrahepatic cholangiocarcinoma. Ann Oncol.
23:2642–2649. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kaira K, Sunose Y, Ohshima Y, Ishioka NS,
Arakawa K, Ogawa T, Sunaga N, Shimizu K, Tominaga H, Oriuchi N, et
al: Clinical significance of L-type amino acid transporter 1
expression as a prognostic marker and potential of new targeting
therapy in biliary tract cancer. BMC Cancer. 13:4822013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hirano S, Kondo S, Tanaka E, Shichinohe T,
Tsuchikawa T, Kato K, Matsumoto J and Kawasaki R: Outcome of
surgical treatment of hilar cholangiocarcinoma: A special reference
to postoperative morbidity and mortality. J Hepatobiliary Pancreat
Sci. 17:455–462. 2010. View Article : Google Scholar
|
|
6
|
Sakamoto Y, Kosuge T, Shimada K, Sano T,
Ojima H, Yamamoto J, Yamasaki S, Takayama T and Makuuchi M:
Prognostic factors of surgical resection in middle and distal bile
duct cancer: An analysis of 55 patients concerning the significance
of ductal and radial margins. Surgery. 137:396–402. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kaufmann E and Knöchel W: Five years on
the wings of fork head. Mech Dev. 57:3–20. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lehmann OJ, Sowden JC, Carlsson P, Jordan
T and Bhattacharya SS: Fox’s in development and disease. Trends
Genet. 19:339–344. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Myatt SS and Lam EW: The emerging roles of
forkhead box (Fox) proteins in cancer. Nat Rev Cancer. 7:847–859.
2007. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Benayoun BA, Caburet S and Veitia RA:
Forkhead transcription factors: Key players in health and disease.
Trends Genet. 27:224–232. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Banham AH, Connors JM, Brown PJ, Cordell
JL, Ott G, Sreenivasan G, Farinha P, Horsman DE and Gascoyne RD:
Expression of the foxp1 transcription factor is strongly associated
with inferior survival in patients with diffuse large B-cell
lymphoma. Clin Cancer Res. 11:1065–1072. 2005.PubMed/NCBI
|
|
12
|
Schuster MB and Porse BT: C/EBPalpha: A
tumour suppressor in multiple tissues? Biochim Biophys Acta.
1766:88–103. 2006.PubMed/NCBI
|
|
13
|
Barrans SL, Fenton JA, Banham A, Owen RG
and Jack AS: Strong expression of FOXP1 identifies a distinct
subset of diffuse large B-cell lymphoma (DLBCL) patients with poor
outcome. Blood. 104:2933–2935. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Banham AH, Beasley N, Campo E, Fernandez
PL, Fidler C, Gatter K, Jones M, Mason DY, Prime JE, Trougouboff P,
et al: The FOXP1 winged helix transcription factor is a novel
candidate tumor suppressor gene on chromosome 3p. Cancer Res.
61:8820–8829. 2001.PubMed/NCBI
|
|
15
|
Lin L, Miller CT, Contreras JI, Prescott
MS, Dagenais SL, Wu R, Yee J, Orringer MB, Misek DE, Hanash SM, et
al: The hepatocyte nuclear factor 3 alpha gene, HNF3alpha (FOXA1),
on chromosome band 14q13 is amplified and overexpressed in
esophageal and lung adenocarcinomas. Cancer Res. 62:5273–5279.
2002.PubMed/NCBI
|
|
16
|
Chen HW, Huang XD, Li HC, He S, Ni RZ,
Chen CH, Peng C, Wu G, Wang GH, Wang YY, et al: Expression of FOXJ1
in hepatocellular carcinoma: Correlation with patients’ prognosis
and tumor cell proliferation. Mol Carcinog. 52:647–659. 2013.
View Article : Google Scholar
|
|
17
|
Lee JS, Chu IS, Heo J, Calvisi DF, Sun Z,
Roskams T, Durnez A, Demetris AJ and Thorgeirsson SS:
Classification and prediction of survival in hepatocellular
carcinoma by gene expression profiling. Hepatology. 40:667–676.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Obama K, Ura K, Li M, Katagiri T, Tsunoda
T, Nomura A, Satoh S, Nakamura Y and Furukawa Y: Genome-wide
analysis of gene expression in human intrahepatic
cholangiocarcinoma. Hepatology. 41:1339–1348. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Pérez-Sánchez C, Arias-de-la-Fuente C,
Gómez-Ferrería MA, Granadino B and Rey-Campos J: FHX.L and FHX.S,
two isoforms of the human fork-head factor FHX (FOXJ2) with
differential activity. J Mol Biol. 301:795–806. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Pérez-Sánchez C, Gómez-Ferrería MA, de La
Fuente CA, Granadino B, Velasco G, Esteban-Gamboa A and Rey-Campos
J: FHX, a novel fork head factor with a dual DNA binding
specificity. J Biol Chem. 275:12909–12916. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang Y, Yang S, Ni Q, He S, Zhao Y, Yuan
Q, Li C, Chen H, Zhang L, Zou L, et al: Overexpression of forkhead
box J2 can decrease the migration of breast cancer cells. J Cell
Biochem. 113:2729–2737. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Shiozaki H, Tahara H, Oka H, Miyata M,
Kobayashi K, Tamura S, Iihara K, Doki Y, Hirano S, Takeichi M, et
al: Expression of immunoreactive E-cadherin adhesion molecules in
human cancers. Am J Pathol. 139:17–23. 1991.PubMed/NCBI
|
|
23
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Murakami Y, Uemura K, Sudo T, Hayashidani
Y, Hashimoto Y, Nakamura H, Nakashima A and Sueda T:
Gemcitabine-based adjuvant chemotherapy improves survival after
aggressive surgery for hilar cholangiocarcinoma. J Gastrointest
Surg. 13:1470–1479. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Igami T, Nishio H, Ebata T, Yokoyama Y,
Sugawara G, Nimura Y and Nagino M: Surgical treatment of hilar
cholangiocarcinoma in the ‘new era’: The Nagoya University
experience. J Hepatobiliary Pancreat Sci. 17:449–454. 2010.
View Article : Google Scholar
|
|
26
|
Lee SG, Song GW, Hwang S, Ha TY, Moon DB,
Jung DH, Kim KH, Ahn CS, Kim MH, Lee SK, et al: Surgical treatment
of hilar cholangiocarcinoma in the new era: The Asan experience. J
Hepatobiliary Pancreat Sci. 17:476–489. 2010. View Article : Google Scholar
|
|
27
|
Unno M, Katayose Y, Rikiyama T, Yoshida H,
Yamamoto K, Morikawa T, Hayashi H, Motoi F and Egawa S: Major
hepatectomy for perihilar cholangiocarcinoma. J Hepatobiliary
Pancreat Sci. 17:463–469. 2010. View Article : Google Scholar
|
|
28
|
Murakami Y, Uemura K, Hayashidani Y, Sudo
T, Hashimoto Y, Ohge H and Sueda T: Prognostic significance of
lymph node metastasis and surgical margin status for distal
cholangiocarcinoma. J Surg Oncol. 95:207–212. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ebata T, Nagino M, Nishio H, Igami T,
Yokoyama Y and Nimura Y: Pancreatic and duodenal invasion in distal
bile duct cancer: Paradox in the tumor classification of the
American Joint Committee on Cancer. World J Surg. 31:2008–2015.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Woo SM, Ryu JK, Lee SH, Yoo JW, Park JK,
Kim YT, Jang JY, Kim SW, Kang GH and Yoon YB: Recurrence and
prognostic factors of ampullary carcinoma after radical resection:
Comparison with distal extrahepatic cholangiocarcinoma. Ann Surg
Oncol. 14:3195–3201. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hong SM, Pawlik TM, Cho H, Aggarwal B,
Goggins M, Hruban RH and Anders RA: Depth of tumor invasion better
predicts prognosis than the current American Joint Committee on
Cancer T classification for distal bile duct carcinoma. Surgery.
146:250–257. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Murakami Y, Uemura K, Sudo T, Hashimoto Y,
Nakashima A, Kondo N, Sakabe R, Ohge H and Sueda T: Prognostic
factors after surgical resection for intrahepatic, hilar, and
distal cholangiocarcinoma. Ann Surg Oncol. 18:651–658. 2011.
View Article : Google Scholar
|
|
33
|
Li Q, Wang JM, Liu C, Xiao BL, Lu JX and
Zou SQ: Correlation of aPKC-iota and E-cadherin expression with
invasion and prognosis of cholangiocarcinoma. Hepatobiliary
Pancreat Dis Int. 7:70–75. 2008.PubMed/NCBI
|
|
34
|
Nitta T, Mitsuhashi T, Hatanaka Y,
Miyamoto M, Oba K, Tsuchikawa T, Suzuki Y, Hatanaka KC, Hirano S
and Matsuno Y: Prognostic significance of epithelial-mesenchymal
transition-related markers in extrahepatic cholangiocarcinoma:
Comprehensive immunohistochemical study using a tissue microarray.
Br J Cancer. 111:1363–1372. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Thiery JP: Epithelial-mesenchymal
transitions in tumour progression. Nat Rev Cancer. 2:442–454. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhang KJ, Wang DS, Zhang SY, Jiao XL, Li
CW, Wang XS, Yu QC and Cui HN: The E-cadherin repressor slug and
progression of human extrahepatic hilar cholangiocarcinoma. J Exp
Clin Cancer Res. 29:882010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Martín-de-Lara F, Sánchez-Aparicio P,
Arias de la Fuente C and Rey-Campos J: Biological effects of FoxJ2
over-expression. Transgenic Res. 17:1131–1141. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Katoh M and Katoh M: Human FOX gene family
(Review). Int J Oncol. 25:1495–1500. 2004.PubMed/NCBI
|
|
39
|
Kehn K, Berro R, Alhaj A, Bottazzi ME, Yeh
WI, Klase Z, Van Duyne R, Fu S and Kashanchi F: Functional
consequences of cyclin D1/BRCA1 interaction in breast cancer cells.
Oncogene. 26:5060–5069. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Chen X, Cao X, Tao G, Cao Z, Wang S, Zhou
F, Xie W, Zhao P, Zhang Z and Cui Z: Foxj2 expression in rat spinal
cord after injury and its role in inflammation. J Mol Neurosci.
47:158–165. 2012. View Article : Google Scholar : PubMed/NCBI
|
